Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.

By D. Logeart, G. Thabut, P. Jourdain, C. Chavelas, P. Beyne, F. Beauvais, E. Bouvier, A. C. Solal. Journal of the American College of Cardiology, 2004

625 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology

View Paper: https://www.semanticscholar.org/paper/d7f944e9a3bd28620537b4111d762a3edafc106a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. T. Horwich
3. J. Januzzi
4. C. Yancy
5. M. Drazner
6. Véronique L. Roger
7. M. Gheorghiade

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “BNP and NT-proBNP levels improve with treatment of chronic HF, with lowering of levels over time in general, correlating with improved clinical outcomes.(248,251,254,260) Thus, BNP or NT-proBNP “guided” therapy has been studied against standard care without natriuretic peptide measurement to determi”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “BNP and NT-proBNP levels improve with treatment of chronic HF (225,272–274), with lowering of levels over time in general, correlating with improved clinical outcomes (248,251,254,260).”